Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 28Completed 10Recruiting 2Not yet recruiting 2Suspended 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Nivolumab 2pembrolizumab 1osimertinib 1icotinib 1famitinib 1dabrafenib 1cemiplimab 1alirocumab 1aldesleukin 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Pemetrexed 1Panitumumab 1Monatide (IMS 3015) 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Interleukin-2 1Injections 1Immune Checkpoint Inhibitors 1Gefitinib 1Eflornithine 1Drug Therapy 1Cisplatin 1Celecoxib 1CTLA-4 Antigen 1Blood Specimen Collection 1Biopsy 1Biological Products 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Carcinoma, Non-Small-Cell Lung × icotinib × Clear all
NCT01720901 2015-05-22

Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy

Betta Pharmaceuticals Co., Ltd.

Phase 4 Suspended
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡